middle.news
Cambium Bio Advances Elate Ocular® with FDA Fast Track and A$3M Capital Raise
1:21pm on Friday 31st of January, 2025 AEDT
•
Healthcare
Read Story
Cambium Bio Advances Elate Ocular® with FDA Fast Track and A$3M Capital Raise
1:21pm on Friday 31st of January, 2025 AEDT
Key Points
FDA grants Fast Track designation for Elate Ocular®
Successful A$3 million capital raise including strategic investor support
Key scientific and board appointments strengthen leadership
Phase 3 clinical trial preparations underway with CRO selection imminent
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Cambium Bio (ASX:CMB)
OPEN ARTICLE